News & Views
ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer imaging product using multi-Curie quantities of cyclotron-produced Gallium-68 via ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target system. …
Read more
Telix has filed a New Drug Submission (NDS) with Health Canada for TLX591-CDx (Kit for the preparation…
Read more
Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field of urologic…
Read more
Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer…
Read more
Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton,…
Read more
Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography…
Read more
Telix Pharmaceuticals announces it has entered into a licensing and partnership agreement with…
Read more
Telix has been granted HREC approval and received CTN clearance by the TGA to commence Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients…
Read more
Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH…
Read more
Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm…
Read more